Never miss a story- keep up to date with the latest news and insights
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions (the “Company”), is today announcing that it has successfully completed its fundraising round for a total of 3,059,910.11 euros through capital increases with preferential subscription rights waived for current shareholders. The offer was subscribed, on the one hand, by professional investors for 2.5 million euros, and, on the other hand, by retail investors through the PrimaryBid platform for 0.6 million euros (the “Transaction”).
Ignacio Faus, NFL Biosciences CEO: “On behalf of NFL Biosciences, I would like to warmly thank all of the professional investors and the many retail investors, through PrimaryBid, who took part in this fundraising round. We have now secured the resources needed to reach the validation milestones of our two main clinical programs on NFL-101 in 2023, and we will also be able to move forward with the development of NFL-301. As always, we will take the greatest care to effectively allocate these resources and we are confident that we will be able to demonstrate the efficacy of NFL-101 in helping people stop smoking”.
This French deal was only available to investors in France.